{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T20:09:49Z","timestamp":1793736589641,"version":"4.6.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Shanghai Municipal \"Explorer Plan\" (the second batch) project in 2024","award":["24TS1411000"],"award-info":[{"award-number":["24TS1411000"]}]},{"name":"Joint Research Development Project between Shenkang and United Imaging on Clinical Research and Translation","award":["SKLY2022CRT201"],"award-info":[{"award-number":["SKLY2022CRT201"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["Youth Fund 82200909"],"award-info":[{"award-number":["Youth Fund 82200909"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Pujiang Program","award":["21PJD012"],"award-info":[{"award-number":["21PJD012"]}]},{"name":"Young and Middle-aged Diabetes Project from Bethune Foundation","award":["Z04JKM2022E002"],"award-info":[{"award-number":["Z04JKM2022E002"]}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFA1802000"],"award-info":[{"award-number":["2023YFA1802000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00125-026-06682-w","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T21:02:54Z","timestamp":1771966974000},"page":"1532-1544","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Canagliflozin attenuates CMR-quantified myocardial fibrosis in individuals with type 2 diabetes mellitus at high cardiovascular risk: a randomised open-label controlled trial"],"prefix":"10.1007","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7341-4368","authenticated-orcid":false,"given":"Hongmei","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaojiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhitian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangshuang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5051-6609","authenticated-orcid":false,"given":"Xinxia","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0308-685X","authenticated-orcid":false,"given":"Xiaoying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1192-671X","authenticated-orcid":false,"given":"Yinyin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5230-8012","authenticated-orcid":false,"given":"Mengsu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"6682_CR1","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41574-022-00669-4","volume":"18","author":"C Ke","year":"2022","unstructured":"Ke C, Narayan KMV, Chan JCN, Jha P, Shah BR (2022) Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations. Nat Rev Endocrinol 18:413\u2013432. https:\/\/doi.org\/10.1038\/s41574-022-00669-4","journal-title":"Nat Rev Endocrinol"},{"key":"6682_CR2","unstructured":"Magliano DJ, Boyko EJ, IDF Diabetes Atlas 10th edition scientific committee (2021) IDF DIABETES ATLAS, 10th edn.\u00a0International Diabetes Federation. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK581934\/"},{"key":"6682_CR3","doi-asserted-by":"publisher","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2022","unstructured":"Sun H, Saeedi P, Karuranga S et al (2022) IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 183:109119. https:\/\/doi.org\/10.1016\/j.diabres.2021.109119","journal-title":"Diabetes Res Clin Pract"},{"key":"6682_CR4","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM et al (2015) EMPAgliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New Engl J Med 373:2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"New Engl J Med"},{"key":"6682_CR5","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. New Engl J Med 377:644\u2013657. https:\/\/doi.org\/10.1056\/NEJMoa1611925","journal-title":"New Engl J Med"},{"key":"6682_CR6","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. New Engl J Med 380:347\u2013357. https:\/\/doi.org\/10.1056\/NEJMoa1812389","journal-title":"New Engl J Med"},{"key":"6682_CR7","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M et al (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:3599\u20133726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"key":"6682_CR8","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D et al (2022) 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines. Circulation 145:e895\u2013e1032. https:\/\/doi.org\/10.1161\/CIR.0000000000001063","journal-title":"Circulation"},{"key":"6682_CR9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/ejhf.696","volume":"19","author":"M Gyongyosi","year":"2017","unstructured":"Gyongyosi M, Winkler J, Ramos I et al (2017) Myocardial fibrosis: biomedical research from bench to bedside. Eur J Heart Fail 19:177\u2013191. https:\/\/doi.org\/10.1002\/ejhf.696","journal-title":"Eur J Heart Fail"},{"key":"6682_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/nrcardio.2012.158","volume":"10","author":"KT Weber","year":"2013","unstructured":"Weber KT, Sun Y, Bhattacharya SK, Ahokas RA, Gerling IC (2013) Myofibroblast-mediated mechanisms of pathological remodelling of the heart. Nat Rev Cardiol 10:15\u201326. https:\/\/doi.org\/10.1038\/nrcardio.2012.158","journal-title":"Nat Rev Cardiol"},{"key":"6682_CR11","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/eurheartj\/eht193","volume":"35","author":"TC Wong","year":"2014","unstructured":"Wong TC, Piehler KM, Kang IA et al (2014) Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission. Eur Heart J 35:657\u2013664. https:\/\/doi.org\/10.1093\/eurheartj\/eht193","journal-title":"Eur Heart J"},{"key":"6682_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1161\/CIRCIMAGING.111.971143","volume":"5","author":"B Pitt","year":"2012","unstructured":"Pitt B, Zannad F (2012) The detection of myocardial fibrosis: an opportunity to reduce cardiovascular risk in patients with diabetes mellitus? Circ Cardiovasc Imaging 5:9\u201311. https:\/\/doi.org\/10.1161\/CIRCIMAGING.111.971143","journal-title":"Circ Cardiovasc Imaging"},{"key":"6682_CR13","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/ehjci\/jeac142","volume":"24","author":"A Di Marco","year":"2023","unstructured":"Di Marco A, Brown PF, Bradley J et al (2023) Extracellular volume fraction improves risk-stratification for ventricular arrhythmias and sudden death in non-ischaemic cardiomyopathy. Eur Heart J Cardiovasc Imaging 24:512\u2013521. https:\/\/doi.org\/10.1093\/ehjci\/jeac142","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"6682_CR14","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s00392-024-02523-1","volume":"114","author":"N Schwegel","year":"2025","unstructured":"Schwegel N, Strohhofer C, Kolesnik E et al (2025) Impact of EMPAgliflozin on cardiac structure and function assessed by echocardiography after myocardial infarction: a post-hoc sub-analysis of the EMMY trial. Clin Res Cardiol 114:629\u2013639. https:\/\/doi.org\/10.1007\/s00392-024-02523-1","journal-title":"Clin Res Cardiol"},{"key":"6682_CR15","doi-asserted-by":"publisher","unstructured":"Fu Q, Zhou L, Fan Y et al (2023) Effect of SGLT-2 inhibitor, dapagliflozin, on left ventricular remodeling in patients with type 2 diabetes and HFrEF.\u00a0BMC Cardiovasc Disord\u00a023:544. https:\/\/doi.org\/10.1186\/s12872-023-03591-3","DOI":"10.1186\/s12872-023-03591-3"},{"key":"6682_CR16","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1161\/CIRCULATIONAHA.120.051992","volume":"143","author":"CY Shim","year":"2021","unstructured":"Shim CY, Seo J, Cho I et al (2021) Randomized, controlled trial to evaluate the effect of dapagliflozin on left ventricular diastolic function in patients with type 2 diabetes mellitus: the IDDIA trial. Circulation 143:510\u2013512. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.051992","journal-title":"Circulation"},{"key":"6682_CR17","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12933-018-0717-9","volume":"17","author":"D Matsutani","year":"2018","unstructured":"Matsutani D, Sakamoto M, Kayama Y, Takeda N, Horiuchi R, Utsunomiya K (2018) Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes. Cardiovasc Diabetol 17:73. https:\/\/doi.org\/10.1186\/s12933-018-0717-9","journal-title":"Cardiovasc Diabetol"},{"key":"6682_CR18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12968-020-00610-6","volume":"22","author":"J Schulz-Menger","year":"2020","unstructured":"Schulz-Menger J, Bluemke DA, Bremerich J et al (2020) Standardized image interpretation and post-processing in cardiovascular magnetic resonance - 2020 update: Society for Cardiovascular Magnetic Resonance (SCMR): Board of Trustees Task Force on Standardized post-processing. J Cardiovasc Magn Reson 22:19. https:\/\/doi.org\/10.1186\/s12968-020-00610-6","journal-title":"J Cardiovasc Magn Reson"},{"key":"6682_CR19","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/1532-429X-15-92","volume":"15","author":"JC Moon","year":"2013","unstructured":"Moon JC, Messroghli DR, Kellman P et al (2013) Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson 15:92. https:\/\/doi.org\/10.1186\/1532-429X-15-92","journal-title":"J Cardiovasc Magn Reson"},{"key":"6682_CR20","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1161\/CIRCULATIONAHA.120.052186","volume":"143","author":"MMY Lee","year":"2021","unstructured":"Lee MMY, Brooksbank KJM, Wetherall K et al (2021) Effect of EMPAgliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation 143:516\u2013525. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.052186","journal-title":"Circulation"},{"key":"6682_CR21","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","volume":"140","author":"S Verma","year":"2019","unstructured":"Verma S, Mazer CD, Yan AT et al (2019) Effect of EMPAgliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial. Circulation 140:1693\u20131702. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.042375","journal-title":"Circulation"},{"key":"6682_CR22","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1093\/eurheartj\/ehaa419","volume":"41","author":"AJM Brown","year":"2020","unstructured":"Brown AJM, Gandy S, McCrimmon R, Houston JG, Struthers AD, Lang CC (2020) A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial. Eur Heart J 41:3421\u20133432. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa419","journal-title":"Eur Heart J"},{"key":"6682_CR23","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.2337\/dc19-2187","volume":"43","author":"JSS Singh","year":"2020","unstructured":"Singh JSS, Mordi IR, Vickneson K et al (2020) Dapagliflozin versus placebo on left ventricular remodeling in patients with diabetes and heart failure: the REFORM trial. Diabetes Care 43:1356\u20131359. https:\/\/doi.org\/10.2337\/dc19-2187","journal-title":"Diabetes Care"},{"key":"6682_CR24","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.jcmg.2020.10.017","volume":"14","author":"T Mason","year":"2021","unstructured":"Mason T, Coelho-Filho OR, Verma S et al (2021) EMPAgliflozin reduces myocardial extracellular volume in patients with type 2 diabetes and coronary artery disease. JACC Cardiovasc Imaging 14:1164\u20131173. https:\/\/doi.org\/10.1016\/j.jcmg.2020.10.017","journal-title":"JACC Cardiovasc Imaging"},{"key":"6682_CR25","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12933-024-02294-z","volume":"23","author":"DD Wang","year":"2024","unstructured":"Wang DD, Naumova AV, Isquith D et al (2024) Dapagliflozin reduces systemic inflammation in patients with type 2 diabetes without known heart failure. Cardiovasc Diabetol 23:197. https:\/\/doi.org\/10.1186\/s12933-024-02294-z","journal-title":"Cardiovasc Diabetol"},{"key":"6682_CR26","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s43044-024-00508-z","volume":"76","author":"A Hassan","year":"2024","unstructured":"Hassan A, Samaan K, Asfour A, Baghdady Y, Samaan AA (2024) Ventricular remodeling and hemodynamic changes in heart failure patients with non-ischemic dilated cardiomyopathy following dapagliflozin initiation. Egypt Heart J 76:76. https:\/\/doi.org\/10.1186\/s43044-024-00508-z","journal-title":"Egypt Heart J"},{"key":"6682_CR27","doi-asserted-by":"publisher","first-page":"7238","DOI":"10.1007\/s00330-023-09689-8","volume":"33","author":"S Zhao","year":"2023","unstructured":"Zhao S, Guo W, Yao Z et al (2023) Fully automated pixel-wise quantitative CMR-myocardial perfusion with CMR-coronary angiography to detect hemodynamically significant coronary artery disease. Eur Radiol 33:7238\u20137249. https:\/\/doi.org\/10.1007\/s00330-023-09689-8","journal-title":"Eur Radiol"},{"key":"6682_CR28","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.jcmg.2021.12.008","volume":"15","author":"DB Salvador Jr","year":"2022","unstructured":"Salvador DB Jr, Gamba MR, Gonzalez-Jaramillo N et al (2022) Diabetes and myocardial fibrosis: a systematic review and meta-analysis. JACC Cardiovasc Imaging 15:796\u2013808. https:\/\/doi.org\/10.1016\/j.jcmg.2021.12.008","journal-title":"JACC Cardiovasc Imaging"},{"key":"6682_CR29","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1186\/s40001-025-02834-7","volume":"30","author":"A Albulushi","year":"2025","unstructured":"Albulushi A, Askari KM, Al-Abedi AM et al (2025) Impact of SGLT2 inhibitors on myocardial fibrosis in diabetic HFpEF: a longitudinal study. Eur J Med Res 30:592. https:\/\/doi.org\/10.1186\/s40001-025-02834-7","journal-title":"Eur J Med Res"},{"key":"6682_CR30","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1186\/s12933-024-02415-8","volume":"23","author":"A Albulushi","year":"2024","unstructured":"Albulushi A, Tanoh DB, Almustafa A et al (2024) Comparative effects of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors on heart failure with preserved ejection fraction in diabetic patients. Cardiovasc Diabetol 23:324. https:\/\/doi.org\/10.1186\/s12933-024-02415-8","journal-title":"Cardiovasc Diabetol"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-026-06682-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-026-06682-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-026-06682-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T11:08:04Z","timestamp":1777028884000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-026-06682-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["6682"],"URL":"https:\/\/doi.org\/10.1007\/s00125-026-06682-w","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"assertion":[{"value":"23 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We would like to express our gratitude to L. Huang and W. Li from the Department of Biostatistics at Zhongshan Hospital, Fudan University, for their supervision and guidance in the statistical analysis of this study. We would also like to extend our thanks to all the individuals who participated in this experiment and the medical staff involved in this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Acknowledgements"}},{"value":"The individual de-identified participant data (including the data dictionary) and statistical code underlying the results reported in this article are not publicly available. However, they will be made available by the corresponding authors upon reasonable request. The datasets generated during and\/or analysed in the current study are available from the corresponding authors upon reasonable request.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"This study was financially supported by the National Key Research and Development programme (2023YFA1802000), the National Natural Science Foundation of China (Youth Fund 82200909), the Young and Middle-aged Diabetes project from the Bethune Foundation (Z04JKM2022E002), the Joint Research Development project between Shenkang and United Imaging on Clinical Research and Translation (SKLY2022CRT201), the Shanghai Municipal \u2018Explorer plan\u2019\u00a0(the second batch) project in 2024 (24TS1411000) and the Shanghai Pujiang programme (21PJD012). The study funders were not involved in the design of the study; the collection, analysis, and interpretation of data; writing the report; and did not impose any restrictions regarding the publication of the report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare that this study received funding support from Merck & Co., Inc., but they were not involved in the study design; collection, analysis, and interpretation of the data; writing of the report; or the decision to submit the report for publication. The authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 relationships and activities"}},{"value":"All authors made substantial contributions to conception and design of the paper. YC, MSZ and HMY were involved in the conception, design and conduct of the study and the analysis and interpretation of the results. HMY, JJL, YYC and ZTZ wrote the first draft of the manuscript; ZTZ, XXC, SSC and JJL conducted the statistical analysis; HMY, YC, XYL, HJ, SSC and YYC contributed to the analysis and interpretation of the data; HMY, JJL, ZTZ, XYL, SSC and XXC contributed to discussions and reviewed and edited the manuscript. All authors edited, reviewed and approved the final version of the manuscript. HMY is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contribution statement"}}]}}